The utility of futility

Stroke

Volumn 36, Issue 11, 2005, Pages 2331-2332

  Levin, Bruce ^a  

^a Columbia University ^*  (United States)

Author keywords

Futility studies; Stroke

Indexed keywords

CEREBROVASCULAR ACCIDENT; EDITORIAL; EXPERIMENTAL DESIGN; METHODOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; ETHICS, MEDICAL; HUMANS; ISCHEMIA; MEDICAL FUTILITY; MODELS, STATISTICAL; QUALITY OF LIFE; RESEARCH DESIGN; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 27644532415     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000185722.99167.56     Document Type: Editorial

References (4)

1. Palesch Y, Tilley BC, Sackett DL, Johnston KC, Woolson R. Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005;36: 2410-2414.
2. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JLP. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. In press.
3. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005;57:197-203.
4. Bechhofer RE, Santner TJ, Goldsman DM. Design and Analysis of Experiments for Statistical Selection, Screening, and Multiple Comparisons. New York: John Wiley & Sons; 1995.